Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5684 in Selected Solid Tumors (OMAHA-015)
NCT06979596Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of opevesostat in breast cancer, ovarian cancer, endometrial cancer (EC), sponsored by Merck & Co.. Started Aug 2025; status: recruiting.
02
Drugs
opevesostat
03
Conditions
breast cancerovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT06979596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979596.